User:Pratima.due/sandbox
_300.png){kind=link}
A lactosylceramide also known as LacCer. Lactosylceramide is a glycosphingolipid comprising of a hydrophobic ceramide lipid and a hydrophilic sugar moiety and is found in microdomains on the plasma layers of numerous cells. Moreover, it is a type of ceramide including lactose, which is an example of a globoside.
Lactosylceramides were initially called 'cytolipin H'. It is found in small amounts just in most creature tissues, however, it has various huge organic capacities and it is of extraordinary significance as the biosynthetic forerunner of the greater part of the impartial oligoglycosylceramides, sulfatides and gangliosides. In creature tissues, biosynthesis of lactosylceramide includes expansion of the second monosaccharides unit (galactose) as its nucleotide subsidiary to monoglucosylceramide, catalyzed by a particular beta-1, 4-galactosyltransferase on the lumenal side of the Golgi mechanical assembly.[1]
|
| |
| Names | |
|---|---|
| IUPAC name
N-(dodecanoyl)-1-beta-lactosyl-sphing-4-enine
| |
| Other names
Lactosylceramide
| |
| Properties | |
| C42H79NO13 | |
| Molar mass | 806.088 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Associated Diorder
[edit]Gaucher's disease is a sphingolipidosis described by a particular inadequacy in acidic glucocerebrosidase, which results in abnormal gathering of glucosylceramide essentially inside the lysosome. Gaucher's disease has been associated with instances of leukemia, myeloma, glioblastoma, lung malignancy, and hepatocellular carcinoma, in spite of the fact that the explanations behind the relationship are at present being discussed.[2]
Some suggest that the impacts of Gaucher's disease might be connected to malignant growth, while others ensnare the treatments used to treat Gaucher's illness. This discussion is not completely astounding, as the theories connecting Gaucher's disease with cancer fail to address the roles of ceramide and glucosylceramide in malignant growth science.
Gaucher disease is caused by mutations in GBA1, which encodes the lysosomal catalyst glucocerebrosidase (GCase). GBA1 transformations drive broad gathering of glucosylceramide (GC) in different natural and versatile resistant cells in the spleen, liver, lung and bone marrow, frequently prompting endless irritation. The systems that interface abundance GC to tissue aggravation stay obscure.[3]
References
[edit]- ^ "Showing metabocard for Lactosylceramide (d18:1/12:0) (HMDB0004866)". Human Metablome Database (HMDB). 2005-04-30. Retrieved 2019-05-23.
- ^ Barth M., Brian; Shanmugavelandy S., Sriram; Tacelosky M., Diana; Kester, Mark; Morad F., Samy A.; Cabot C., Myles (1 January 2014). "Gaucher's Disease and Cancer: a Sphingolipid Perspective". National Center for Biotechnology Information. Retrieved 25 May 2019.
{{cite web}}: Cite has empty unknown parameter:|1=(help) - ^ Pandey, MK.; Burrow, TA.; Rani, R.; Martin, LJ.; Witte, D.; Setchell, KD.; Magnusen, AF.; Zhang, W.; Liou, B.; Köhl, J.; Grabowski, GA. (2 March 2017). "Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease". National Center for Biotechnology Information. Retrieved 25 May 2019.